Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Prognosis and treatment options are stage dependent. In general, prognosis of patients with unresectable HCC is poor, especially for those...Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Prognosis and treatment options are stage dependent. In general, prognosis of patients with unresectable HCC is poor, especially for those patients with impaired liver function. Whereas treatment with the novel molecular tyrosine kinase inhibitor sorafenib (Nexavar) was shown to result in prolonged survival in patients with preserved liver function, its' possible application in HCC-patients with strongly impaired liver function has not been clearly assessed. Here, we report on a 47-year-old male patient who presented with Child-Pugh class C liver cirrhosis and multifocal, non-resectable HCC. The patient was treated for 27 mo with Sorafenib, which was not associated with major drug-related side effects. During treatment, a reduction in tumour size of 24% was achieved, as assessed by regular CT scan. Moreover,within the 27 mo interval of stable tumour disease, liver function improved from Child-Pugh class C to class A.展开更多
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with major morbidity and mortality.Therapeutic management is difficult,due to lack of conclusive data and individual disease progression.High-do...Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with major morbidity and mortality.Therapeutic management is difficult,due to lack of conclusive data and individual disease progression.High-dose UDCA was used for years as a pharmacotherapeutic agent to prevent disease progression,based on a positive trend in pilot studies,but has recently been proven to have a negative effect in advanced disease.Immunosuppressants might be useful in patients with overlap syndromes.Dominant bile duct stenoses should be treated endoscopically,and cholangiocellular carcinoma (CCC) still remains a therapeutic challenge in PSC patients.Early diagnosis of CCC must be improved and new strategies such as neoadjuvant radiochemotherapy with subsequent liver transplantation in selected patients are further options to be considered.展开更多
文摘Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Prognosis and treatment options are stage dependent. In general, prognosis of patients with unresectable HCC is poor, especially for those patients with impaired liver function. Whereas treatment with the novel molecular tyrosine kinase inhibitor sorafenib (Nexavar) was shown to result in prolonged survival in patients with preserved liver function, its' possible application in HCC-patients with strongly impaired liver function has not been clearly assessed. Here, we report on a 47-year-old male patient who presented with Child-Pugh class C liver cirrhosis and multifocal, non-resectable HCC. The patient was treated for 27 mo with Sorafenib, which was not associated with major drug-related side effects. During treatment, a reduction in tumour size of 24% was achieved, as assessed by regular CT scan. Moreover,within the 27 mo interval of stable tumour disease, liver function improved from Child-Pugh class C to class A.
文摘Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with major morbidity and mortality.Therapeutic management is difficult,due to lack of conclusive data and individual disease progression.High-dose UDCA was used for years as a pharmacotherapeutic agent to prevent disease progression,based on a positive trend in pilot studies,but has recently been proven to have a negative effect in advanced disease.Immunosuppressants might be useful in patients with overlap syndromes.Dominant bile duct stenoses should be treated endoscopically,and cholangiocellular carcinoma (CCC) still remains a therapeutic challenge in PSC patients.Early diagnosis of CCC must be improved and new strategies such as neoadjuvant radiochemotherapy with subsequent liver transplantation in selected patients are further options to be considered.
